SubsidieMeestersProtein Ruler to Create Affordable Biosensor Diagnosis for the Many
This project aims to develop a simple, portable, and cost-effective quantitative test for ovarian cancer biomarkers to enhance early detection and improve patient outcomes.
Projectdetails
Introduction
Ovarian cancer is the most common malignancy of the female reproductive system worldwide, and the leading cause of death from gynecological cancer. However, if diagnosed during the early stages, patients have a good prognosis, with around a 90% 5-year survival rate.
Current Challenges
Despite its lethality, there are currently no effective simple tests for diagnosis nor population-based screening techniques for ovarian cancer. Emerging tests detecting cancer biomarkers have the potential for the greatest impact for surveillance and early detection, such as the FDA-approved CA125 and HE4 biomarkers.
Importance of Quantitative Testing
Importantly, because the levels of these biomarkers are not the same among all healthy females and increase with age, these tests should be quantitative. Current quantitative diagnostic tests for CA125 and HE4 detection are expensive, require high-cost infrastructures, and trained professionals.
Need for Innovation
Therefore, there is an urgent need for developing cheap, reliable, easy-to-use quantitative tests for ovarian cancer biomarkers. In this project, ground-breaking innovative research will give rise to novel technology, enabling the detection of cancer biomarkers in a manner that is quantitative, and yet simple, portable, and cheap.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-9-2023 |
| Einddatum | 28-2-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- LUNDS UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Epigenetic profiling of menstrual blood for precision cancer detection and preventionThe EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers. | ERC Proof of... | € 150.000 | 2024 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC Proof of... | € 150.000 | 2024 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Ruthenium-containing Polymers against Ovarian CancersThis project aims to enhance survival rates in advanced ovarian cancer by validating a novel ruthenium-based drug delivery system in patient-derived xenograft models to overcome platinum resistance. | ERC Proof of... | € 150.000 | 2023 | Details |
Building consensus for a new approach to breast cancer prevention in women with a BRCA1 mutationThis project aims to establish consensus for a clinical trial using progesterone receptor antagonists to prevent breast and ovarian cancer in women with BRCA1 mutations. | ERC Proof of... | € 150.000 | 2023 | Details |
Epigenetic profiling of menstrual blood for precision cancer detection and prevention
The EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.
Ruthenium-containing Polymers against Ovarian Cancers
This project aims to enhance survival rates in advanced ovarian cancer by validating a novel ruthenium-based drug delivery system in patient-derived xenograft models to overcome platinum resistance.
Building consensus for a new approach to breast cancer prevention in women with a BRCA1 mutation
This project aims to establish consensus for a clinical trial using progesterone receptor antagonists to prevent breast and ovarian cancer in women with BRCA1 mutations.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
STA-OPHet project ontwikkelt een op maat gemaakte therapie voor eierstokkanker om de levensduur en kwaliteit van leven van patiënten te verbeteren. | 1.1 - Het ve... | € 482.805 | 2023 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanningProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly. | EIC Accelerator | € 1.987.387 | 2021 | Details |
Innovatieve diagnostiek voor verbetering screening naar gynaecologische kankerHet project richt zich op het ontwikkelen van een efficiëntere en vrouwvriendelijke screening voor gynaecologische kankers. | 1.1 - Onderz... | € 600.000 | 2022 | Details |
Voorkomen van therapieresistentie bij kankerDit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren. | Mkb-innovati... | € 20.000 | 2021 | Details |
STA-OP
Het project ontwikkelt een op maat gemaakte therapie voor eierstokkanker om de levensduur en kwaliteit van leven van patiënten te verbeteren.
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning
ProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly.
Innovatieve diagnostiek voor verbetering screening naar gynaecologische kanker
Het project richt zich op het ontwikkelen van een efficiëntere en vrouwvriendelijke screening voor gynaecologische kankers.
Voorkomen van therapieresistentie bij kanker
Dit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren.